Clinical Review: Topical Ophthalmic Use of Cyclosporin A

REFERENCES

• De Smet MD, Nussenblat RB. Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin. 1993;33:31–45.
   PubMedGoogle Scholar
• Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today. 1993;14:290–295.
   PubMedGoogle Scholar
• Nussenblat RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159–169
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321–338.
   PubMed Web of Science ®Google Scholar
• Foulks G. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46:105–122
   PubMedGoogle Scholar
• Kashani S, Mearza AA. Uses and safety profile of cyclosporin in ophthalmology. Expert Opin. Drug Saf. 2008;7:79–89.
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977;32:1017–1025.
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–475.
   PubMedGoogle Scholar
• Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323–1327.
   PubMed Web of Science ®Google Scholar
• Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea. 1990;9:184–195.
   PubMed Web of Science ®Google Scholar
• Williams DL. A comparative approach to topical cyclosporin therapy. Eye. 1997;11:453–464.
   PubMed Web of Science ®Google Scholar
• Coster DJ, Shepherd WF, Fook TC, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet. 1979;2, 688–689.
   PubMed Web of Science ®Google Scholar
• Hunter PA, Wilhelmus KR, Rice NS, et al. Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol. 1981;45:173–177.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Wiederholt M. [Local treatment of corneal transplants in the human with cyclosporin A.] Klin Monatsbl Augenheilkd. 1985;187:92–96.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12:413–419.
   PubMed Web of Science ®Google Scholar
• Gunduz K, Ozden O. Therapeutic use of topical cyclosporine. Ann Ophthalmol. 1993;25:182–186.
   Google Scholar
• Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247–261.
   PubMed Web of Science ®Google Scholar
• Bettelman E, Pleyer U. Immunomodulatory therapy in ophthalmology—is there a place for topical application? Ophthalmologica. 2004;218:359–367.
   PubMed Web of Science ®Google Scholar
• Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield: a new vehicle for delivery of cyclosporin A to the eye. Cornea. 1990;9:196–199.
   PubMed Web of Science ®Google Scholar
• Kanai A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporine eye drops. Transplant Proc. 1989;21: 3150–3152.
   PubMed Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res. 1999;18:91–103.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631–639.
   PubMed Web of Science ®Google Scholar
• Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002;18:411–418.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107:967–974.
   PubMed Web of Science ®Google Scholar
• Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta Ophthalmol (Copenh). 1994;72: 438–442.
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105: 1715–1720.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337–342.
   PubMed Web of Science ®Google Scholar
• Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45:211–220.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res. 2004;23:449–474.
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: Report of The Definition and Classification Subcommittee of The International Dry Eye Workshop (2007). Ocul Surf. 2007; 5(2):75–92.
   Google Scholar
• Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409–416.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjogren’s syndrome. Ann N Y Acad Sci. 1999;876:312–324.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporin 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315–323.
   PubMed Web of Science ®Google Scholar
• Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren’s syndrome. Cornea. 1993;12:507–511.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporin. Arch Ophthalmol. 2002;120:330–337.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.
   PubMed Web of Science ®Google Scholar
• Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporin ophthalmic emulsion. Cornea. 2000;19:492–496.
   PubMed Web of Science ®Google Scholar
• Roberts CW, Elie ER. Dry eye symptoms following cataract surgery. Insight. 2007;32:14–21.
   PubMedGoogle Scholar
• Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006;32:772–778.
   PubMed Web of Science ®Google Scholar
• Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2009 Aug 31 [Epub ahead of print]
   Google Scholar
• Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28:1091–1096.
   PubMed Web of Science ®Google Scholar
• Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol. 2009;147:919–923.
   PubMed Web of Science ®Google Scholar
• Cheung J, Sharma S. Ophthaproblem: blepharitis. Can Fam Physician. 2000;46:2393–2400.
   Google Scholar
• McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea. 2000;19:650–658.
   PubMed Web of Science ®Google Scholar
• Kocak-Altintas AG, Kocak-Midillioglu I, Gul U, et al. Impression cytology and ocular characteristics in ocular rosacea. Eur J Ophthalmol. 2003;13:351–359.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Ozaki A, Fukata K, et al. Age-specific recognition, activation, and effector function of T-cells in the conjunctiva with experimental immunemediated blepharoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44:4366–4374.
   PubMed Web of Science ®Google Scholar
• Carreras I, Carreras B, McGrath L, et al. Activated T-cells in an animal model of allergic conjunctivitis. Br J Ophthalmol. 1993;77:509–514.
   Google Scholar
• Magone MT, Chan CC, Rizzo LV, et al. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol. 1998;87:75–84.
   Google Scholar
• Liu G, Keane-Myers A, Miyazaki D, et al. Molecular and cellular aspects of allergic conjunctivitis. Chem Immunol. 1999;73:39–58.
   Google Scholar
• Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006;22:47–53.
   PubMed Web of Science ®Google Scholar
• Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171–175.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Merchant A, Pinar V, et al. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863–1867.
   PubMed Web of Science ®Google Scholar
• Doan S, Gabison E, Gatinel D, et al. Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis. Am J Ophthalmol. 2006;141:62–66.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:1–9.
   Google Scholar
• Allansmith MR. Vernal conjunctivitis. In: Duane TD, Jaeger EA, eds. Clinical Ophthalmology, rev ended. Philadelphia, PA: Harper & Row; 1986: 1.
   Google Scholar
• Collum LM. Vernal keratoconjunctivitis. Acta Ophthalmol Scand Suppl. 1999: 77: 14–16.
   Google Scholar
• Ukponmwan CU. Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases. Trop Doct. 2003;33:242–245.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Ross-Degnan D. Blindness in Saudi Arabia. JAMA. 1986;255:3378–3384.
   PubMed Web of Science ®Google Scholar
• Herse P, Gothwal VK. Survey of visual impairment in an Indian tertiary eye hospital. Indian J Ophthalmol. 1997;45:189–193.
   PubMedGoogle Scholar
• Abu el-Asrar AM, Van den Oord JJ, Geboes K, et al. Immunopathological study of vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 1989;227:374–379.
   PubMed Web of Science ®Google Scholar
• el-Asrar AM, Tabbara KF, Geboes K, et al. An immunohistochemical study of topical cyclosporin in vernal keratoconjunctivitis. Am J Ophthalmol. 1996;121:156–161.
   PubMed Web of Science ®Google Scholar
• El Hennawi M. A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis. Br J Ophthalmol. 1994;78:365–369.
   PubMed Web of Science ®Google Scholar
• Bonini S, Barney NP, Schiavone M, et al. Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis. Eye. 1992;6:648–652.
   PubMed Web of Science ®Google Scholar
• Foster CS. Evaluation of cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology. 1988;95:194–201.
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Cornand G, Filliard G, et al. Limbal vernal keratoconjunctivitis in the tropics. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1988;65:21–72.
   Google Scholar
• Baryishak YR, Zavaro A, Monselise M, et al. Vernal keratoconjunctivitis in an Israeli group of patients and its treatment with sodium cromoglycate. Br J Ophthalmol. 1982;66:118–122.
   PubMedGoogle Scholar
• Abiose A. Paediatric ophthalmic problems in Nigeria. J Trop Pediatr. 1985;31:30–35.
   Google Scholar
• Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88–92.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Hasiripi H, Christen WG, et al. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology. 2000;107:263–269.
   PubMed Web of Science ®Google Scholar
• BenEzra D, Pe’er J, Brodsky M, et al. Cyclosporin eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986;101:278–282.
   PubMed Web of Science ®Google Scholar
• Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporin in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110:641–645.
   PubMed Web of Science ®Google Scholar
• Bleik JH, Tabbara KF. Topical cyclosporin in vernal keratoconjunctivitis. Ophthalmology. 1991;98:1679–1684.
   PubMed Web of Science ®Google Scholar
• Avunduk AM, Avunduk MC, Erdol H, et al. Cyclosporin effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica. 2001;215:290–293.
   PubMed Web of Science ®Google Scholar
• Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298–303.
   PubMed Web of Science ®Google Scholar
• Cetinkaya A, Akova YA, Dursun D, et al. Topical cyclosporin in the management of shield ulcers. Cornea. 2004;23:194–200.
   PubMed Web of Science ®Google Scholar
• Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527–532.
   PubMed Web of Science ®Google Scholar
• Garrity JA, Liesegang TJ. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19:19–24.
   Google Scholar
• Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology.1998;105:637–642.
   PubMed Web of Science ®Google Scholar
• Belfort R, Marbeck P, Hsu CC, et al. Epidemiological study of 134 subjects with allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 2000;230:38–40.
   Google Scholar
• Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150–158.
   PubMed Web of Science ®Google Scholar
• Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology. 1991;98:1190–1196.
   PubMed Web of Science ®Google Scholar
• Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100:817–824.
   PubMed Web of Science ®Google Scholar
• Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29:1214–1222.
   PubMed Web of Science ®Google Scholar
• Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97:992–1000.
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105:1715–1720.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476–482.
   PubMed Web of Science ®Google Scholar
• Tomida I, Schlote T, Brauning J, et al. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis.] Ophthalmologe. 2002;99:761–767.
   Google Scholar
• Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90:461–464.
   PubMed Web of Science ®Google Scholar
• Hingorani M, Calder VL, Buckley RJ, et al. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 1999;40:392–399.
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–372.
   PubMed Web of Science ®Google Scholar
• Williams KA, Muehlberg SM, Barlett CM, et al. Report from the Australian Corneal Graft Registry. Adelaide: Flinders University Press; 2007.
   Google Scholar
• Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361–402.
   Google Scholar
• Hudde T, Minassian DC, Larkin DFP. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348–1352.
   PubMed Web of Science ®Google Scholar
• Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection: oral versus single pulse therapy. Ophthalmology. 1991;98:329–333.
   PubMed Web of Science ®Google Scholar
• Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25:286–290.
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J. 1998;24:159–165.
   PubMedGoogle Scholar
• Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785–1790.
   PubMed Web of Science ®Google Scholar
• Poon A, Constantinou M, Lamoureux E, et al. Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008;36:415–421.
   PubMed Web of Science ®Google Scholar
• Lelli GJ, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GvHD. Cornea. 2006;25:635–638.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22:S19–S27.
   PubMed Web of Science ®Google Scholar
• Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4–13.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83:1125–1130.
   PubMed Web of Science ®Google Scholar
• Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation, I: clinical study. Arch Ophthalmol. 1983;101:580–584.
   PubMedGoogle Scholar
• Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GvHD. Invest Ophthalmol Vis Sci. 2001;42:111–119.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kuwana M, Yamazaki K, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2003;44:1888–1896.
   PubMed Web of Science ®Google Scholar
• Rao SN, Rao RD. Efficacy of topical cyclosporine. 05% in the treatment of dry eye associated with graft versus host disease. Cornea. 2006;25:674–678.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ogawa Y, Dogru M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008;41:293–302.
   PubMed Web of Science ®Google Scholar
• Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology. 1984;91:1253–1263.
   PubMed Web of Science ®Google Scholar
• Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogren’s syndrome. Arch Ophthalmol. 1980;98:89–94.
   PubMedGoogle Scholar
• Zierhut M, Thiel HJ, Weidle EG, et al. Topical treatment of severe corneal ulcers with cyclosporin A. Graefes Arch Clin Exp Ophthalmol. 1989;227:30–35.
   Google Scholar
• Kervick GN, Pflugfelder SC, Haimovici R, et al. Paracentral rheumatoid corneal ulceration: clinical features and cyclosporin therapy. Ophthalmology. 1992;99:80–88.
   PubMed Web of Science ®Google Scholar
• Gottsch JD, Akpek EK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 2000;98:81–87.
   PubMedGoogle Scholar
• Liegner JT, Yee RW, Wild JH. Topical cyclosporin therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610–612.
   PubMed Web of Science ®Google Scholar
• Thygeson P. Superficial punctate keratitis. JAMA. 1950;144:1544–1549.
   Google Scholar
• Nagra PK, Rapuano CJ, Cohen EJ, et al. Thygeson’s superficial punctuate keratitis: ten years’ experience. Ophthalmology. 2004;111:34–37.
   PubMed Web of Science ®Google Scholar
• Hardten DR, Doughman DJ, Holland EJ, et al. Persistent superficial punctuate keratitis after resolution of chlamydial follicular conjunctivitis. Cornea. 1992;11:360–363.
   Google Scholar
• Reinhard T, Roggendorf M, Fengler I, et al. PCR for varicella zoster virus genome negative in corneal epithelial cells of patients with Thygeson’s superficial punctate keratitis. Eye. 2004;18:304–305.
   Google Scholar
• Goldberg DB, Schanzlin DJ, Brown SI. Management of Thygeson’s superficial punctate keratitis. Am J Ophthalmol. 1980;89:22–24.
   Google Scholar
• Forstot SL, Binder PS. Treatment of Thygeson’s superficial punctuate keratopathy with soft contact lenses. Am J Ophthalmol. 1979;88:186–189.
   Google Scholar
• Reinhard T, Sundmacher R. [Local cyclosporin A therapy in Thygeson superficial punctate keratitis—a pilot study.] Klin Monatsbl Augenheilkd. 1996;209:224–227.
   Google Scholar
• Reinhard T, Sundmacher R. Topical cyclosporin A in Thygeson’s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:109–112.
   PubMed Web of Science ®Google Scholar
• Del Castillo JM, Del Castillo JB, Garcia-Sanchez J. Effect of topical cyclosporine A on Thygeson’s superficial punctate keratitis. Doc Ophthalmol. 1996–97;93:193–198.
   Google Scholar
• Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol. 2003;48:369–388.
   PubMed Web of Science ®Google Scholar
• Hidayat AA, Riddle PJ. Ligneous conjunctivitis: a clinicopathologic study of 17 cases. Ophthalmology. 1987;94:949–959.
   Google Scholar
• Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol. 2002;133:451–455.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Chan CC, Kuwabara T, et al. Immunohistologic findings and results of treatment with cyclosporin in ligneous conjunctivitis. Am J Ophthalmol. 1989;107:160–166.
   PubMed Web of Science ®Google Scholar
• Rao SK, Biswas J, Rajagopal R, et al. Ligneous conjunctivitis: a clinicopathologic study of 3 cases. Int Ophthalmol. 1998–1999;22:201–206.
   PubMed Web of Science ®Google Scholar
• Rubin BI, Holland EJ, de Smet MD, et al. Response of reactivated ligneous conjunctivitis to topical cyclosporin. Am J Ophthalmol. 1991;112:95–96.
   PubMed Web of Science ®Google Scholar
• Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. 1991;25:593–619.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Nikolskaia OV, et al. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol. 2003;136:239–243.
   PubMed Web of Science ®Google Scholar
• Neumann R, Dutt CJ, Foster CS. Immunohistopathologic features and therapy of conjunctival lichen planus. Am J Ophthalmol. 1993;115:494–500.
   PubMed Web of Science ®Google Scholar
• Oliver GF, Winkelmann RK. Treatment of lichen planus. Drugs. 1993;45:56–65.
   Google Scholar
• Levell NJ, Munro CS, Marks JM. Severe lichen planus clears with very low dose cyclosporin. Br J Dermatol. 1992;127:66–67.
   PubMed Web of Science ®Google Scholar
• Crompton DO. Immuno-suppressive drug treatment of keratitis sicca, including an example of lichen planus of the conjunctiva. Aust N Z J Surg. 1968;38:143–146.
   PubMedGoogle Scholar
• Leonardi A, DeFranchis G, Fregona IA, et al. Effects of cyclosporin A on human conjunctival fibroblasts. Arch Ophthalmol. 2001;119:1512–1517.
   PubMed Web of Science ®Google Scholar
• Rhee MK, Mootha VV. Bilateral keratoconjunctivitis associated with lichen planus. Cornea. 2004;23:100–105.
   PubMed Web of Science ®Google Scholar
• Pakravan M, Klesert T, Akpek EK. Isolated lichen planus of the conjunctiva. Br J Ophthalmol. 2006;90:1325–1326.
   PubMed Web of Science ®Google Scholar
• Theodore FH. Further observations on superior limbic keratoconjunctivitis. Trans Am Acad Ophthalmol Otolaryngol. 1967;71:341–351.
   PubMedGoogle Scholar
• Cher I. Superior limbic keratoconjunctivitis: multifactorial mechanical pathogenesis. Clin Exp Ophthalmol. 2000;28:181–184.
   PubMed Web of Science ®Google Scholar
• Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Topical cyclosporin A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology. 2003;110:1578–1581.
   PubMed Web of Science ®Google Scholar
• Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997;29:405–408.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237:435–438.
   PubMed Web of Science ®Google Scholar
• Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006;141:771–772.
   PubMed Web of Science ®Google Scholar
• Reynolds SA, Kabat AG. Therapeutic options for the management of early neurotrophic keratopathy: a case report and review. Optometry. 2006;77:503–507.
   Google Scholar
• Zhao JC, Jin XY. Immunological analysis and treatment of Mooren’s ulcer with cyclosporin A applied topically. Cornea. 1993;12:481–488.
   PubMedGoogle Scholar
• Shimura M, Yasuda K, Fuse N, et al. Effective treatment with topical cyclosporin A of a patient with Cogan syndrome. Ophthalmologica. 2000;214:429–432.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Ilhan-Sarac O, Green WR. Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva. Arch Ophthalmol. 2003;121:1333–1335.
   PubMed Web of Science ®Google Scholar
• McCoombes JA, Hirst LW, Green WR. Use of topical cyclosporin for conjunctival manifestations of actinic prurigo. Am J Ophthalmol. 2000;130:830–831.
   Google Scholar
• Derse M, Wannke E, Payer H, et al. [Successful topical cyclosporin A in the therapy of progressive vascularising keratitis in keratitis-ichthyosis-deafness (KID) syndrome (Senter syndrome).] Klin Monatsbl Augenheilkd. 2002;219:383–386.
   Google Scholar
• Chung MS, Pepose JS, El-Agha MS, et al. Confocal microscopic findings in a case of delayed-onset bilateral diffuse lamellar keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28:1467–1470.
   Google Scholar
• Touzeau O, Borderie V, Razavi S, et al. [Use of topical cyclosporin in microcrystalline keratopathy due to streptococcus.] J Fr Ophtalmol. 1999;22:662–665.
   Google Scholar
• Gumus K, Mirza E, Cavanagh HD, et al. Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of literature. Eye & Contact Lens. 2009;5:275–278.
   Google Scholar